At the time this article was written, Erin Martin was a student in the PA program at Mercer University in Atlanta, Ga. She now practices at Resurgens Orthopaedics in Atlanta, Ga., specializing in shoulder and elbow. Catherine K. Sadowski is a clinical associate professor in the PA program at Mercer University. The authors have disclosed no potential conflicts of interest, financial or otherwise.
JAAPA. 2024 May 1;37(5):1-5. doi: 10.1097/01.JAA.0000000000000013. Epub 2024 Apr 25.
Traditionally, medical providers have used the step-up approach to manage patients with Crohn disease, starting with 5-aminosalicylic acid derivatives, progressing to corticosteroids, and eventually to immunomodulators and biologics. However, a new top-down approach focuses on early and aggressive therapy with biologics and immunomodulators to reduce the rate of mucosal and intestinal damage. This article describes early and aggressive biologic and immunomodulator therapies and new therapeutic parameters compared with traditional step-up treatment for patients with Crohn disease.
传统上,医疗提供者采用逐步升级的方法来治疗克罗恩病患者,从 5-氨基水杨酸衍生物开始,逐步使用皮质类固醇,最终使用免疫调节剂和生物制剂。然而,一种新的自上而下的方法侧重于早期和积极的生物制剂和免疫调节剂治疗,以降低粘膜和肠道损伤的速度。本文描述了与传统逐步升级治疗相比,用于克罗恩病患者的早期和积极的生物和免疫调节剂治疗以及新的治疗参数。